Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option

Alessandra Iurlo, Daniele Cattaneo, Nicola Orofino, Cristina Bucelli, Matteo Molica, Massimo Breccia

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)475-476
Number of pages2
JournalClinical Drug Investigation
Issue number5
Publication statusPublished - 2018

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this